In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Retatrutide vs. Tirzepatide: The Next Gen GLP 1 Showdown Tirzepatide: a new low for bodyweight and blood glucose The Lancet Diabetes & Endocrinology Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question